

Making Cancer History[®]



Creating Path to Cancer Free Communities Sten Ry Sten

Targeted & Immunotherapy: The New Era in Cancer Management

Friday, April 7, 2017 Saturday, April 8, 2017

> Double Tree by Hilton 8181 Airport Blvd. Houston, TX 77061

> > Time: 8 a.m.-5 p.m.

Goal: Improve Use of Immunotherapy and Targeted Therapy in Cancer Management

PLANNING COMMITTEE

Chairman: Aung Naing, MD, Associate Professor Investigational Cancer Therapeutics Department The University of Texas MD Anderson Cancer Center

Co-Chair Lonzetta L. Newman, MD, FACP? Associate Professor, Clinical Cancer Prevention The University of Texas MD Anderson Cancer Center

Co-Chair: Eucharia Iwuanyanwu, DHSC, PA-C, FAAPA President, Ace Cancer Care, Inc. Physician Assistant, Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center

> Diane Barber, PhD, APRN, ANP-BC, AOCNP Advanced Practice Nurse Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center

> Joan Lim, PharmD, BCSP Clinical Pharmacy Specialist Pharmacy Clinical Programs The University of Texas MD Anderson Cancer Center

> Tamara C. Greiner, MA, CCMEP Associate Director, CME/Conference Management The University of Texas MD Anderson Cancer Center

Goal

There has been a paradigm shift in the management of patients with advanced cancer from "one size fits all" to providing personalized therapy tailored to the molecular landscape of the tumor. However, in recent years, breakthrough discoveries of immune checkpoints and durable responses observed with immunotherapeutic agents has been more transformative and has led to regulatory approval of the several checkpoint inhibitors for specific indications.

Prompted by the success of these checkpoint inhibitors, increasing number of immunotherapeutic agents are being investigated across the tumor board, which presents unique challenges to the treating physician. As immunotherapy works by unleashing the suppressed immune system to attack tumor cells rather than attacking the tumor cells directly, immunotherapeutic agents differ significantly from chemotherapeutic agents and consequently pose monitoring and managing toxicity challenges for medical teams, community oncologists, emergency room physicians, etc. Furthermore, with success being made with these drugs, more and more cancer patients are demanding these drugs as first line therapies for the management of their cancers.

Our seminar seek to provide an avenue for bringing the academic researchers and the community providers who are all interested in winning the fight against cancer together as first step in bridging the knowledge gap and to provide a means of disseminating research findings for practice application.

Educational Objectives

- Participants will demonstrate understating of the pathophysiology of the drugs and there application
- Become competent in application of these drugs in cancer management including in combination with cytotoxic drugs
- Be able to differentiate between true and pseudo-progression while on drugs
- Recognize and manage toxicities associated with the drugs early to avoid disastrous outcomes for patients
- Identify and avoid contraindications to these drugs.

Target Audience

- Physicians
- Physician Assistants
- Pharmacists
- Advanced Practice Registered Nurses
- Registered Nurses
- Students

Educational Methods

- Lectures Case Presentation Including Interactive Audience Participation
- Question and Answer Sessions

Evaluation

A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

Accreditation/Credit Designation

The University of Texas MD Anderson Cancer Center is an approved provider of Physician and Physician Assistant continuing medical education by the American Medical Association, an accredited approver

CME application has been submitted to The University of Texas MD Anderson Cancer Center for approval.

AAPA accepts certificates of participation for educational activities certified for AMA *PRA Category 1 Credit*TM from organizations accredited by ACCME or a recognized state medical society.

Nursing continuing education will be provided

This activity has been submitted to the Oncology Nursing Society for approval to award contact hours. ONS is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center's COA

CME Certificates

Certificates awarding AMA PRA Category 1 CreditsTM or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians and Physician Assistants must submit a completed evaluation questionnaire and a CME Verification Form.

Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

Listing of Speakers/Authors

Hwu, Patrick, MD

Head, Division of Cancer Medicine Dept. Chair, Melanoma Medical Oncology Dept. Chair, Sarcoma Medical Oncology The University of Texas MD Anderson Cancer Center

Lonzetta L. Newman, MD, FACP

Associate Professor, Clinical Cancer Prevention The University of Texas MD Anderson Cancer center

Hussein Twabi, MD, Professor

Dept. of Melanoma The University of Texas M.D. Anderson Cancer Center

David Hong, MD, Associate Professor

Dept. of Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center

Vivik Subbiah, MD, Associate Professor

Dept. of Investigational cancer Therapeutics The University of Texas MD Anderson Cancer Center

Myrisha Woods, PA-C

Dept. of Cardiology The University of Texas MD Anderson Cancer Center

Naval Daver, MD. Assistant Professor

Dept. of Leukemia The University of Texas MD Anderson Cancer center

Gautam Borthakur, MD Dept. of Leukemia

The University of Texas MD Anderson Cancer center

Allyson Price, PA-C

Dept. of Leukemia The University of Texas MD Anderson Cancer center

Gao, Jianjun, MD Associate Professor

Dept. of Urology The University of Texas M.D. Anderson Cancer Center

Windy Dean Colomb, MD, PhD

Medical Director Oncology Medical Director Oncology Research, University Hospital and Clinics, Lafayette, Louisiana

Liz Waxman, APRN

Dept. of Thoracic/Head and Neck Medical Oncology The University of Texas M.D. Anderson Cancer Center

Amir A, Jazaeri, MD, Associate Professor

Dept. of Gynecological Oncology The University of Texas MD Anderson Cancer Center

Aung Naing, MD, Professor

Dept. of Investigational Cancer Therapeutics The University of Texas M.D. Anderson Cancer Center

Mathai Abey, PA-C

Dept. of Lymphoma The University of Texas MD Anderson Cancer Center

Joud Hajjar MD

Assistant Professor of Medicine Dept. of Immunology, Allergy & Rheumatology Baylor College of Medicine and Texas Children's Hospital

JoAnn T Lim, PharmD, BCOP

Clinical Pharmacy Specialist The University of Texas MD Anderson Cancer Center

Agenda, Day 1- April 7

7:30 - 8:15 a.m.	Breakfast			
8:15 - 8:30 a.m.	Introduction of Program and First Speaker			
8:30 - 9:00 a.m.	Immunotherapy in Cancer Management Hwu, Patrick, MD Division Head, Can Med Administration The University of Texas MD Anderson Cancer center			
9:00 -9:55 a.m.	Immunotherapy and Targeted Therapy and Cancer Prevention Lonzetta L. Newman, MD, FACP Associate Professor, Clinical Cancer Prevention The University of Texas MD Anderson Cancer center			
9:55-10:40 a.m.	Pathophysiology and Response of Immunotherapy JoAnn T Lim, PharmD, BCOP, Clinical Pharmacy Specialist The University of Texas MD Anderson Cancer Center			
10:40-11:40 a.m.	Melanoma and Immunotherapy: Better Outcome Hussein Twabi, MD, Professor Dept. of Melanoma The University of Texas M.D. Anderson Cancer Center			
11:50-12:30 p.m.	Lunch/Lecture (No CME)			
12:40-1:40 p.m.	Changing Landscape of clinical trials David Hong, MD, Associate Professor Dept. of Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center			
1:40-2:40 p.m.	Immunotherapy for Lymphoma Mathai Varghese, PA-C Dept. of Lymphoma The University of Texas MD Anderson Cancer Center			

2:40-2:50 p.m.	Break
2:50-3:35 p.m.	Immune Based Therapies in AML and MDS Naval Daver, MD. Assistant Professor Dept. of Leukemia The University of Texas MD Anderson Cancer center
3:35-4:20 p.m.	Targeted Therapy in Leukemia Management Gautam Borthakur, MD Dept. of Leukemia The University of Texas MD Anderson Cancer center
4:20-5.00 p.m.	Introduction to Car T cell Therapy With an Emphasis of Cytokine Release Syndrome and Neurotoxicity Allyson Price, PA-C Dept. of Leukemia The University of Texas MD Anderson Cancer center

Agenda, Day 2 – April 8

7:30-8:10 a.m.	Breakfast				
8:10-8:15 a.m.	Introduction of Program and First Speaker				
8:15-8:45 a.m.	Cardiotoxicity of Immuno and Targeted Therapy Myrisha Woods, PA-C Dept. of Cardiology The University of Texas MD Anderson Cancer Center				
8:45-9:45 a.m.	Immunotoxicities: What to Expect and how to Manage Vivik Subbiah, MD, Associate Professor Dept. of Investigational cancer Therapeutics The University of Texas MD Anderson Cancer Center				
9:45 -10:45 a.m.	Immunotherapy and application in Breast Cancer Management Windy Dean-Colomb, MD Medical Director Oncology Medical Director Oncology Research, University Hospital and Clinics, Lafayette, Louisiana				
10:45 -11:45 a.m.	Genitourinary: Immune Checkpoint Therapy for GU Malignancies and Toxicity Management. Gao, Jianjun, MD Associate Professor Dept. of Urology The University of Texas M.D. Anderson Cancer Center				
11:45 -11:55 p.m.	Break				
12:00 -12:50 p.m.	Lunch/Lecture				
1:00 – 2:00 p.m.	Updates in Lung Cancer Liz Waxman, APRN Dept. of Thoracic/Head and Neck Medical Oncology The University of Texas M.D. Anderson Cancer Center				

2:00 – 3:00 p.m.	Recent Advances in Immune and Targeted Therapies in Gynecological Oncology Amir A, Jazieri, MD, Associate Professor Dept. of Gynecological Oncology The University of Texas MD Anderson Cancer Center			
3:00-3:10 p.m.	Break			
3:10-4:10 p.m.	Biomarkers and Correlates of Clinical Response in Cancer Immunotherapy Joud Hajjar MD Assistant Professor of Medicine Dept. of Immunology, Allergy & Rheumatology Baylor College of Medicine and Texas Children's Hospital			
4:10 0-4:40 p.m.	Future Directions: Immunotherapy for the New Age Aung Naing, MD, Professor Dept. of Investigational Cancer Therapeutics The University of Texas M.D. Anderson Cancer Center			





Making Cancer History®

Creating Path to Cancer Free Communities, Step By Step

Registration Information

On-site registration for Ace Cancer Care Inc. opens at 7:00 a.m. on Tuesday, January 31, 2017.

Advance registration is encouraged as space and materials are limited. Please see registration form for applicable fees.

The deadline for advance registration is March 10, 2017.

There are three ways to register:

- Mail to: 6011 Telephone Road, Houston TX, 77087
- Fax to: 713-645-5588
- On-line at: <u>www.acecancercareinc.org</u>

We accept the following forms of payment:

- Check (payable through U.S. banks only)
- Money Order
- Credit Cards (MasterCard, VISA, and American Express) via PayPal
- Cash (on-site registration only)

A receipt and confirmation letter will be sent to you within ten working days of receipt of your fee.

The full conference registration fee includes:

Physicians: \$300
Fellows: \$250
Physician Assistants, Pharmacists, and Advanced Practice Nurses: \$230
Registered Nurses: \$150

Registration Form:

Category:	Physician:	PA/APN:	Pharmacists:	Registered Nurse		
Name:						
Degree:						
Address:						
City:			State:	Zip Code:		
Professiona	l Affiliation:					
Phone #:						
Email Address:						
Method of payment: Check: Make out to Africa cancer Care Inc. (Mail to 6011 Telephone						
Road, Houston TX 77087)						
Online: at <u>www.acecancercareinc.org</u>						
Onsite Registration: Check or Cash. No Credit Cards Please						

Refund and Cancellation Policy

The registration fee, minus a \$50 administrative handling fee, is refundable if a written request is received on or before April 1st, 2017. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.

ACCI reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or the contact phone numbers as given on the registration form.

In case of activity cancellation, liability of ACCI is limited to the registration fee. ACCI will refund the full registration fee. ACCI reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.

For additional information, contact ACCI at 713-995-8000.

Accommodation

A block of rooms has been reserved for seminar attendees at Double Tree by Hilton Hotel,

8181 Airport Blvd., Houston, TX 77061

- Early hotel reservation is suggested.
- The hotel phone number is (713) 645-3000
- Room Reservation Website

https://secure3.hilton.com/en_US/dt/reservation/book.htm?execution=e1s1

Special Assistance

Contact ACCI at 713-995-8000 if you have any special dietary or ADA accommodation needs.

Ground Transportation

The hotel is 1.1 miles from Hobby Airport. Taxis are available at the approximate price of \$10 one way. The hotel is 29.1 miles from IAH, takes about 33 minutes from IAH airport and costs more.